Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
241
-
242
-
243
-
244
-
245
-
246
-
247
-
248
-
249
-
250
-
251
-
252
-
253
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
254
-
255
-
256
-
257
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
258
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
259
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
260